A Gut Bacterium, a Saturated Fat, and a Surprising Clue About Heart Disease

The surprising discovery

What if a substance produced by bacteria in your gut could help your body remove cholesterol from the bloodstream and slow the buildup of plaque in your arteries?

A study published in Nature on October 7, 2026, investigated a gut bacterium called Bacteroides uniformis and a molecule it produces. In experiments involving mice, the bacterium and its associated metabolite improved cholesterol-related measures and reduced atherosclerotic plaque burden compared with untreated controls.

The molecule is pentadecanoic acid, commonly abbreviated C15:0. It belongs to a family of fats known as saturated odd-chain fatty acids.

The findings are intriguing because they suggest that a molecule classified as a saturated fat can have beneficial biological effects in a specific experimental setting.

But the distinction matters: the study did not show that eating more saturated fat reverses heart disease. It investigated a particular bacterial metabolite in laboratory experiments, primarily involving male mice. It also did not establish that the bacterium or molecule prevents heart attacks or reverses coronary artery disease in people.

What did the researchers investigate?

The team began by examining whether differences in the gut microbiome—the community of microorganisms living in our intestines—might be associated with atherosclerosis.

Atherosclerosis develops when cholesterol-containing particles and other material accumulate within artery walls, forming plaques that can narrow arteries or contribute to heart attacks and strokes.

The researchers compared gut-microbiome data from 223 healthy people and 189 people with cardiovascular disease. They identified differences in bacterial populations, with members of the Bacteroides group attracting particular interest. One species, Bacteroides uniformis, became a focus of the investigation.

These human comparisons provided a starting point, not proof of causation. Differences in gut bacteria might contribute to disease, reflect the effects of disease, or arise from differences in diet, medication use, or other health factors.

To investigate whether the bacterium could directly influence atherosclerosis, the researchers conducted experiments in mice genetically predisposed to develop the disease.

What happened in the mice?

The researchers used ApoE-deficient mice, which are particularly susceptible to atherosclerosis. The animals were exposed to a high-fat, high-sugar diet and studied following different interventions involving B. uniformis and C15:0.

The experiments reported several important findings:

• Less plaque accumulation: Mice receiving the bacterium or its associated metabolite developed less atherosclerotic plaque than untreated controls.
• Improved blood-lipid measures: The researchers reported reductions in LDL cholesterol and triglycerides in the experimental animals.
• Changes in cholesterol regulation: The findings implicated pathways involved in liver cholesterol production and LDL-receptor expression.
• Reduced inflammation: The researchers reported less inflammatory immune-cell infiltration in affected arteries and other findings consistent with an anti-inflammatory effect.
• No improvement in every metabolic measure: The reported experiments did not show corresponding improvements in insulin sensitivity or body weight, although liver weight was modestly reduced.

Two additional experiments strengthened the argument that C15:0 played a role in the effect. Engineered bacteria that produced less C15:0 provided weaker protection, while heat-killed bacteria did not produce the same benefit. These findings support the importance of the bacterium’s metabolic activity and the molecule it produces, although they do not establish that C15:0 is the only relevant factor.

An important limitation is that the experiments used male mice. The findings therefore do not establish whether the effects would be similar in female animals, much less in men and women.

Did the treatment reverse existing plaque?

This is one of the most important distinctions in interpreting the study.

The researchers compared plaque burden at the end of the experiments between treated mice and untreated controls. The findings showed less plaque in the treated groups.

However, the study did not establish that the mice started with the same measured plaque burden and then experienced a reduction from that baseline.

Less plaque at the end of an experiment is not the same as shrinking plaque that already exists. The findings are consistent with slower plaque progression under the experimental conditions, not demonstrated reversal of established atherosclerosis.

That distinction matters because a treatment that slows the development of new plaque may have different implications from one that reliably reduces existing plaque in people.

The study is an encouraging step in understanding a possible mechanism. It is not evidence that C15:0 can clear existing human coronary blockages.

How could a gut-bacteria molecule affect cholesterol?

The researchers identified pentadecanoic acid, or C15:0, as a key molecule associated with the bacterium’s effects. Their findings implicated HMG-CoA reductase, an enzyme involved in the liver’s production of cholesterol.

That enzyme is already familiar to people who take statins.

Statins, including atorvastatin, inhibit HMG-CoA reductase. This reduces cholesterol synthesis and triggers changes in the liver that help increase the removal of LDL particles from the bloodstream.

The researchers also reported changes in the liver’s cholesterol-regulating pathways, including LDL-receptor expression. These receptors help remove LDL particles from circulation.

In simplified terms, the proposed pathway is:

1. The gut bacterium produces C15:0.
2. C15:0 influences cholesterol-related pathways in the liver.
3. The liver’s cholesterol-regulating machinery changes, including pathways involving LDL receptors.
4. Changes in cholesterol handling, together with reduced inflammation, may help explain the lower plaque burden observed in treated mice.

The mechanism is interesting, but the size and clinical importance of these effects in humans remain unknown.

Is C15:0 a natural statin?

It is tempting to describe C15:0 as a natural statin because the study implicates the same cholesterol-production enzyme targeted by statin drugs. But that comparison needs considerable caution.

The study included an atorvastatin comparison. According to a secondary analysis of the paper by Lifespan.io, atorvastatin produced a greater plaque-reduction effect than C15:0 at the same reported dose of 25 mg/kg. The secondary account also describes C15:0 as a weaker inhibitor of the enzyme. The live-bacteria comparison likewise does not justify claiming that the bacterial treatment outperformed atorvastatin.

These comparisons were made under specific experimental conditions in mice. They do not establish equivalent doses, safety, or effectiveness in humans.

A treatment’s clinical value depends on far more than whether it affects the same enzyme as an established medicine. Researchers must determine its absorption, metabolism, effective dose, duration of action, adverse effects, interactions, and—most importantly—whether it improves meaningful health outcomes in people.

Statins have extensive clinical-trial evidence demonstrating that lowering LDL cholesterol reduces cardiovascular risk. C15:0 does not yet have comparable human evidence.

This study is a reason to investigate a possible new biological pathway, not a reason to replace a prescribed cholesterol-lowering medicine.

The human findings: a clue, not proof

The human microbiome comparisons provide a reason to investigate the relationship between B. uniformis, C15:0, and cardiovascular disease further.

But an association between a bacterial species or metabolite and health status cannot establish that restoring it will prevent or treat disease.

People with different cardiovascular health may differ in diet, medication use, underlying conditions, and many other factors. Observational studies cannot reliably separate all these influences.

Human clinical trials would be needed to determine whether changing the abundance of this bacterium or the amount of C15:0 in the body improves cholesterol levels, slows atherosclerosis, or reduces cardiovascular events.

Does this mean saturated fat is good for your arteries?

No. That conclusion goes beyond the evidence.

C15:0 is a saturated fatty acid, but its classification does not determine its effects in every biological context. Different fatty acids can behave differently, and the effects of a specific molecule depend on its dose, metabolism, and biological setting.

Importantly, the researchers administered C15:0 directly to mice by oral gavage—a controlled method of delivering a measured dose through a feeding tube. That demonstrates that the administered molecule can have an effect under the experimental conditions.

It does not establish what dose would be effective or safe in humans, whether ordinary foods could produce a comparable exposure, or whether a commercially available supplement would deliver the same result.

The study did not demonstrate that eating butter, fatty meat, coconut oil, or other foods rich in saturated fat reverses atherosclerosis. Nor did it show that a diet high in saturated fat is beneficial for cardiovascular health.

A specific saturated fatty acid producing a beneficial effect in a mouse experiment is not evidence that saturated fat as a dietary category protects human arteries.

Is LDL cholesterol still a problem if your metabolism is healthy?

Metabolic health matters. High blood pressure, diabetes, smoking, inflammation, and other factors can influence the development and progression of atherosclerosis. Triglycerides, insulin sensitivity, and other markers provide useful information about cardiovascular risk.

But a healthy metabolic profile does not make elevated exposure to LDL-containing particles harmless.

Genetic research, population studies, and randomized clinical trials provide strong evidence that LDL-containing particles play a causal role in atherosclerosis. These particles can enter and become retained in artery walls, contributing to plaque development. The number of atherogenic particles, the duration of exposure, and other risk factors all matter.

A person can be physically fit, have low triglycerides, and have normal blood sugar while still developing significant coronary artery disease. Conversely, lowering LDL does not eliminate every other cardiovascular risk.

The new microbiome research does not overturn this evidence. It may eventually reveal another way to influence cholesterol metabolism and inflammation alongside established prevention strategies.

What about the foods we eat every day?

The study naturally raises questions about whether everyday foods can increase C15:0 levels or encourage the bacteria that produce it.

Those are reasonable questions, but this research does not yet answer them.

The experiments do not establish that a particular food reliably increases beneficial C15:0 production in the human gut, that eating more of it reduces artery plaque, or that a supplement delivers the same biological effect as the controlled experimental treatment.

Even if a food contains C15:0, the amount consumed, absorption, metabolism, and the dose reaching relevant tissues could all influence its effects.

Before recommending a food or supplement specifically to fight atherosclerosis, researchers would need evidence that it changes the relevant biological pathway in people and improves meaningful health outcomes.

For now, this study is not a reason to start a C15:0 supplement, deliberately increase saturated-fat intake, or alter a prescribed treatment plan.

What needs to happen next?

Several questions remain:

• Can the findings be reproduced independently and in different experimental models?
• Are the effects similar in female mice?
• Does C15:0 influence cholesterol metabolism in humans at achievable and safe doses?
• Can researchers demonstrate benefits beyond changes in blood tests or plaque measurements in animals?
• Does the approach slow atherosclerosis in people or reduce heart attacks, strokes, and other cardiovascular events?
• What are the long-term safety profile and potential interactions with existing medications?

The researchers disclosed that one author was an inventor on a pending patent application covering the use of C15:0 for preventing or treating atherosclerosis. A patent interest does not invalidate scientific findings, but it is relevant context when evaluating claims about a potential future treatment.

The bottom line

This study connects three important areas of research: gut bacteria, the liver’s cholesterol-regulating machinery, and atherosclerotic plaque.

A molecule produced by a gut bacterium reduced plaque burden and improved lipid measures in mice. The engineered-bacteria and heat-killed-bacteria experiments add support to the proposed biological explanation. Human observations provide another reason to investigate the connection.

But this is still preliminary evidence. The experiments involved male mice, did not establish shrinkage of existing plaque from a measured baseline, and do not demonstrate that C15:0 prevents cardiovascular events in humans.

The discovery may eventually contribute to new ways of managing cardiovascular risk. It does not currently show that eating saturated fat reverses heart disease, that a probiotic can clear human arteries, or that established cholesterol-lowering treatments can be replaced.

Scientific breakthroughs are worth following with an open mind. The key is to stay curious without letting an exciting early result become a stronger claim than the evidence supports.